Literature DB >> 2785530

Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma.

C D Mills1, M D Caldwell, D S Gann.   

Abstract

The etiology of immunodeficiency following trauma was investigated. Plasma collected from Fischer rats 1-8 hr following a 40% surface area thermal injury (TI) displays immunosuppressive activity (ISA). Peak ISA (4 hr) exceeded 90% inhibition of Con A3-induced proliferation of normal spleen cells. Splenic macrophage IL-1 secretion and NK activity are also inhibited by 4-hr TI plasma. Most importantly, these same cellular immune functions decline in rats by 4 hr following TI. After a further decline by 16 hr (IL-1 = 19.8% and NK activity = 40% of normal), these cellular immune functions rebound toward normal values by 2 days following TI. Thus, ISA in plasma is both temporally and functionally linked to the cellular immune defects observed. Sham-treatment rats display a similar, although less marked, pattern of plasma-linked transient cellular immune defects indicating a role for stress in these responses. ISA is abolished by mild heat (56 degrees C for 30 min) and wholly contained in the greater than 10-kD fraction of plasma. Together, these results provide evidence that previously unrecognized molecules in plasma induce a "window" of immunodeficiency early following trauma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785530     DOI: 10.1007/bf00916942

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  45 in total

1.  The temporal characteristics of the metabolic and endocrine response to injury.

Authors:  J F Amaral; J D Shearer; B Mastrofrancesco; D S Gann; M D Caldwell
Journal:  J Trauma       Date:  1988-09

2.  Thermal injury, intravascular hemolysis, and toxic oxygen products.

Authors:  J R Hatherill; G O Till; L H Bruner; P A Ward
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Alterations of the immune response following severe thermal injury.

Authors:  J W Alexander; J A Moncrief
Journal:  Arch Surg       Date:  1966-07

5.  Is there an interleukin 2 inhibitor in human serum?

Authors:  R Lelchuk; J A Schmidt; K Hodson; R Aston; F Y Liew
Journal:  Cell Immunol       Date:  1987-01       Impact factor: 4.868

6.  Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1.

Authors:  K M Brown; A V Muchmore; D L Rosenstreich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis.

Authors:  R N Stephan; T S Kupper; A S Geha; A E Baue; I H Chaudry
Journal:  Arch Surg       Date:  1987-01

8.  Oxygen radical dependent lung damage following thermal injury of rat skin.

Authors:  G O Till; C Beauchamp; D Menapace; W Tourtellotte; R Kunkel; K J Johnson; P A Ward
Journal:  J Trauma       Date:  1983-04

9.  The immunosuppressive activity of C1q degradation peptides.

Authors:  J L Ninnemann; A N Ozkan
Journal:  J Trauma       Date:  1987-02

10.  Lipid peroxidation and acute lung injury after thermal trauma to skin. Evidence of a role for hydroxyl radical.

Authors:  G O Till; J R Hatherill; W W Tourtellotte; M J Lutz; P A Ward
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

View more
  2 in total

1.  Acute release of cytokines is proportional to tissue injury induced by surgical trauma and shock in rats.

Authors:  H Bitterman; A Kinarty; H Lazarovich; N Lahat
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

2.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.